Carregant...
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of care for the treatment of metastatic non‐small cell lung cancer...
Guardat en:
| Publicat a: | Cancer Commun (Lond) |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8045926/ https://ncbi.nlm.nih.gov/pubmed/33689225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cac2.12153 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|